阿尔茨海默病风险因子BIN1与神经支架蛋白p140Cap之间的相互作用的生物物理和分子特征
Danielle M Blazier1, Eric M Lewandowski2, Natasha Ram1
1Byrd Alzheimer's Center and Research Institute, University of South Florida, Tampa, FL 33613.
The Journal of biological chemistry
|September 1, 2025
概括
桥梁整合剂1 (BIN1) 与神经元蛋白p140Cap相互作用,影响阿尔茨海默病的风险. 这项研究确定了p140Cap作为BIN1结合伙伴,揭示了BIN1变异如何影响这些关键相互作用.
科学领域:
- 神经科学
- 分子生物学
- 遗传学
背景情况:
- 桥梁整合物1 (BIN1) 是已知的晚期阿尔茨海默病的遗传风险因素.
- 在非神经元细胞中已经确定了BIN1在内细胞和行为动态中的作用,但其神经元功能,特别是突触囊泡动态,仍然不清楚.
- 对于蛋白质与蛋白质的相互作用至关重要,BIN1具有保存的Src同质性3 (SH3) 域.
研究的目的:
- 识别神经元中的新型BIN1相互作用蛋白.
- 描述BIN1与神经支架蛋白p140Cap之间的相互作用.
- 研究一种罕见的BIN1变体对其结合相互作用的影响.
主要方法:
- 表面等离子共振 (SPR) 来确定结合亲和力和确定关键结合动机.
- 氨酸扫描突变生成以绘制交互部位.
- 聚焦显微镜和近距离结合试验 (PLA) 用于同位化研究.
- 共同免疫沉和谷氨S转移酶 (GST) 下拉测试以验证相互作用和评估变异效应.
主要成果:
- 神经支架蛋白p140Cap被确定为与BIN1 SH3域相互作用的蛋白质.
- 在p140Cap中,两个富含proline的II类基因与KD为7. 7μM的BIN1结合.
- 在培养细胞和小鼠大脑组织中确认了BIN1和p140Cap的同位化.
- 一种罕见的BIN1编码变体 (rs138047593) 显著降低了p140Cap和tau的结合亲和力.
结论:
- 这项研究确定p140Cap是神经元中BIN1的新型结合伙伴.
- 鉴定到的BIN1- p140Cap相互作用是由p140Cap中特定的富含proline的基因介导的.
- 一种与疾病相关的BIN1变体损害了其结合关键相互作用伙伴的能力,包括p140Cap和tau,这表明它在阿尔茨海默病的发病过程中的作用机制.
- 需要进一步的研究来阐明BIN1:p140Cap相互作用对神经元功能的功能后果.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
09:35Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain
Published on: October 24, 2017
12.3K
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...